Swiss pharmaceutical company Novartis is investing $300 million ($288 million) in biotherapeutics development, which includes a new $100 million biologics hub at its home base in Basel.
This content was published on
1 minute
swissinfo.ch/mga
Português
pt
Novartis vai gastar 300 milhões de dólares em bioterapias
A further $110 million will be spent on research and production at a Novartis site in Slovenia and $60 million in Austria, the company announcedExternal link on Monday.
Biotherapeutics is a growing class of medicaments which are extracted or synthesized from biological material, including proteins, cells and genes to treat such conditions as cancer and autoimmune diseases.
“Across the industry, biotherapeutics account for almost one-half of all recent new drug approvals and have enormous potential to address unmet need across a wide range of diseases,” said Reto Fischer, Head of Technical Research Division, Global Drug Development.
The new Swiss biologics hub will be created on the Basel St Johann campus in Basel to complement the company’s existing NIBR biologics centre.
The Basel-headquartered Novartis, one of the world’s largest pharmaceutical companies, is currently undergoing a restructuring process. In June, it announced that 8,000 jobs would be cut from its 108,000 global work force. The 1,400 Swiss jobs that will disappear represents some 10% of the staff it employs in its home market.
Employees in Switzerland increasingly stressed at work
This content was published on
The proportion of people in Switzerland who are stressed at work has increased by 5% over ten years, according to the Federal Statistical Office.
This content was published on
F/A-18 fighter jets will practice take offs and landings on the A1 motorway between Payerne and Avenches in canton Vaud on June 5.
Swisscom finalises financing for Vodafone Italia takeover
This content was published on
Telecoms group Swisscom has taken the next step in its takeover of Vodafone Italia and secured financing for the deal, the company said on Thursday.
This content was published on
The recent decision by the Swiss drugmaker to shed 7% of its workforce is more than just a cost-cutting measure - it’s a turning point for Novartis.
Novartis job cuts to heavily impact management roles
This content was published on
Of the 1,400 job cuts announced by the pharma giant in Switzerland, up to half of them will involve executive-level staff.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.